Status:
COMPLETED
Osteoporosis Prevention With Low Dose Alendronate
Lead Sponsor:
University Hospital of Mont-Godinne
Conditions:
Osteopenia
Eligibility:
FEMALE
45-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic ...
Eligibility Criteria
Inclusion
- 45 to 60 year-old women
- Menopausal since at least 6 months
- Baseline lumbar BMD from -1 till -2.5
Exclusion
- Bone disease other than osteopenia
- Treatment with selective estrogen receptor modulator (SERMs), calcitonin or hormone replacement therapy within 6 monts prior to randomization
- Former or current treatment with any bisphosphonate or bone forming agents
- Chronic use of oral or iv corticosteroids
- Any diagnosis of malignancy less than 12 months
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00463268
Start Date
September 1 2007
End Date
January 1 2012
Last Update
May 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University (UCL) Louvain Hospital in Mont-Godinne
Yvoir, Namur, Belgium, 5530